Center for Biologics Evaluation and Research

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

CDCs 21 Goals. CDC Strategic Imperatives 1. Health impact focus: Align CDCs people, strategies, goals, investments & performance to maximize our impact.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
T HE R OAD A HEAD LAC-DPH Strategic Plan Wendy K. Schiffer, MSPH Director of Planning, Evaluation, & Development County of Los Angeles Department of Public.
Biopharmaceutical Quality
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
5th Annual PBM Pharmacy Informatics Conference
Directions for this Template  Use the Slide Master to make universal changes to the presentation, including inserting your organization’s logo –“View”
Laboratory of Immunobiochemistry Site Visit
Laboratory of Respiratory and Special Pathogens. History of the Laboratories Laboratory of Pertussis Laboratory of Respiratory and Special Pathogens Laboratory.
Reorganization of APHIS Veterinary Services U.S. Department of Agriculture Animal and Plant Health Inspection Service Veterinary Services November 2013.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
Overview of the Division of Viral Products
Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,
Office of Cellular Tissue and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Cellular, Tissue, and.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Michael J. Brennan, Ph.D. for Kathryn M. Carbone, M.D. Associate Director for.
The NIH Roadmap for Medical Research
Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 28 February 2012.
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
“Critical Path” for Food and Nutrition Science Board November 5, 2004 Alan M. Rulis.
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
Associate Director for Research, OCTGT
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.
LIB site visit January 24, 2002 Jay E. Slater, MD Laboratory of Immunobiochemistry FDA/CBER/OVRR/DBPAP.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 12 May 2011.
DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.
The Integrated National Biodefense Portfolio Initiative “One-Portfolio” Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF) May 6, 2009.
Office of Science U.S. Department of Energy U.S. Department of Energy Office of Science Jerry Elwood Director, Climate Change Research Division, Office.
FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.
Laboratory of Immunobiochemistry Ronald L. Rabin, MD Allergenic Products Advisory Committee 18 March 2009.
OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
Office of Vaccines Research and Review
Office of Human Research Protection Georgia Health Sciences University.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.
CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
Office of Science Statement on Digital Data Management Laura Biven, PhD Senior Science and Technology Advisor Office of the Deputy Director for Science.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Peer Review of OBP Research Division of Monoclonal Antibodies
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
CBER Research: OCTGT Office Site Visit Carolyn A. Wilson, Ph.D. Associate Director of Research (Acting) CBER/FDA.
David M. Murray, Ph.D. Associate Director for Prevention Director, Office of Disease Prevention Multilevel Intervention Research Methodology September.
Mission SUPPORT BASIC RESEARCH TO DEVELOP DRUGS, DIAGNOSTICS, AND VACCINES FOR EMERGING AND REEMERGING INFECTIONS AND BIODEFENSE. The Duke RBL supports.
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
CDRH 2010 Strategic Priorities
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
American Society for Quality Region 5 Quality Conference
Presentation transcript:

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn A. Wilson, Ph.D. Associate Director for Research

CBER Strategic Plan for Regulatory Science Follows CBER’s Strategic Goals Increase national preparedness to address threats from bioterrorism, pandemic and EIDs Improve global public health through international collaboration Enhance ability of science and technology to facilitate development of safe and effective biological products Ensure safety of biological products Advance regulatory science and research Manage for organizational excellence CBER Strategic Plan FY2012-2016: http://www.fda.gov/downloads/aboutfda/centersoffices/cber/ucm266867.pdf CBER’s Strategic Plan for Regulatory Science and Research: http://www.fda.gov/downloads/BiologicsBloodVaccines/ScienceResearch/UCM303542.pdf

Using Science and Regulation to Advance Product Development Novel Product Regulatory Challenge Public Health Science Discovery New Tools Policy/Decision Licensed Product Improved Data – Benefit/Risk + Opportunity to use WO move to re-engage scientific staff in the mission of CBER and that includes the critical role that research plays to support our regulatory mission. CBER research is filling gaps in scientific knowledge in order to overcome obstacles to product development 3

CBER researcher = “Researcher-Regulator” ~20% CBER Staff Integration of research and review ensures Relevance, Expertise, Timeliness, and Usability

CBER Advances Regulatory Science through External Collaborations Data from FY13 CBER Research Reporting Database

Annual Review of Research PI provides For each project Progress report Future plans Budget Request Presentations, Pubs Other output Information reviewed Lab chief, DD, ADR, OD Relevance Productivity Quality Research Reporting Database Funding Allocated Relevance to priority Scientific/Reg Output Feasiblity

Cyclic Peer Review of Every PI Every 4 Years External – Site Visits peer review by scientific experts Internal – Promotion, Conversion, Evaluation Committee

Site-Visit Report Draft report is distributed to full Advisory Committee Final report is approved by full Advisory Committee Final report used in many ways: Internal peer review of research/PI by Promotion, Conversion, Evaluation Committee (PCE) for personnel actions By PIs for improving research program By management, resource allocation decisions may be impacted by report (pending resource availability)

Office of Vaccines Research and Review Slides Courtesy of Konstantin Chumakov, PhD Associate Director for Research, OVRR

Office of Vaccines Research and Review Director Marion Gruber, Ph.D. Deputy Director Philip Krause, M.D. Associate Director for Research Konstantin Chumakov, Ph.D. Associate Director for Medical Policy and Vaccine Safety Karen Farizo, M.D. Associate Director For Management and Scientific Affairs Erik Henchal, Ph.D. Associate Director for Regulatory Policy Theresa Finn, Ph.D. Division of Bacterial, Parasitic and Allergenic Products Director: Jay Slater, M.D. Deputy: Drusilla Burns, Ph.D. Division of Viral Products Director: Jerry Weir, Ph.D. Deputy: Robin Levis, Ph.D. Division of Vaccines and Related Products Applications Director: Wellington Sun, Ph.D. Deputy: Loris McVittie, Ph.D. OVRR Mission Statement: To protect and enhance the public health by assuring the availability of safe and effective vaccines, allergenic extracts, and other related products.

OVRR Regulatory Portfolio Bacterial vaccines (inactivated) – 10 Bacterial vaccines (live attenuated) – 2 Viral vaccines (inactivated) – 10 Viral vaccines (live attenuated) – 15 Combination products (inactivated) – 4 Allergenic extracts (diagnostic and therapeutic) >2,000 Live biotherapeutic products – INDs only

OVRR Core Activities Review, evaluate, and take appropriate actions on INDs, BLAs, amendments and supplements to these applications for vaccines and related products, conducting inspections, etc. Develop policies and procedures governing the pre-market review of regulated products Conducting research related to the development, manufacture, and evaluation of vaccines and related products

OVRR Regulatory Challenges Emphasis on SAFETY: Products for mass use (often universal) Recipients are healthy individuals, often children Short regulatory cycle Seasonal influenza vaccines Response to emerging pathogens (pandemic vaccines) Many products are old Innovative technologies Research plays a critical role in regulation of vaccines

OVRR Research Priorities Safety To study factors affecting safety of regulated products, create and validate appropriate methods and standards Efficacy To study biomarkers and introduce new methods and standards to evaluate and improve vaccine efficacy Availability To develop new concepts and methods opening novel regulatory pathways to improve availability of vaccines and related products

Annual Program Review Cycle Senior Investigator Lab Chief Division Director Research Management Committee Office IOD

Looking Forward 2014: Moving to White Oak Campus 16

White Oak Lab Facility State-of-the-Art Vivarium Imaging facility with MRI, digital X-ray, IVIS, ultrasound Transgenic derivation facility Expanded Space for Core Technologies: Flow cytometry Confocal microscopy High throughput sequencing and bioinformatic support 10 BSL-3 suites Designed to support work of at least 12 infectious agents and work of 36 PI’s Many suites with capacity for animal holding rooms 1 suite to support sterile sorts and live cell confocal microscopy on BSL-3 agents Insectariums (BSL-2 and BSL-3) Suites designed to support Microarray and PCR Expanded NMR facility and Mass Spec Suites 17

Your input improves CBER’s research programs Thank you! To the Site Visit reviewers and Advisory Committee Your input improves CBER’s research programs External review is critical to fulfilling our regulatory mission!